狼疮性肾炎肾血管损害和miR-145的表达

目的评估狼疮性肾炎(LN)患儿肾血管损害(RVLs)并检测肾血管中mi R-145的表达。方法收集41例经肾活检证实为LN的系统性红斑狼疮(SLE)患儿的临床资料,评估肾小球损害和RVLs。根据RVLs评分及病理类型分组。采用原位杂交法检测mi R-145在肾血管中的表达。比较不同病理分型组间RVLs、肾血管mi R-145表达及肾小球损害评分差异;比较不同RVLs组间临床指标、肾小球损害评分及肾血管mi R-145表达差异。结果不同LN病理类型间,RVLs的差异无统计学意义(P0.05),肾血管mi R-145表达及肾小球损害评分差异有统计学意义(P0.01)。不同RVLs组间,临床指标及肾小球损害差异均无统计学意义(P0.05),而肾血管mi R-145表达差异有统计学意义(P0.01)。结论 LN患儿存在RVLs,mi R-145可能参与RVLs的发生机制。     

肝硬化患者血清miR-122的表达及与Child-Pugh分级的关系

目的探讨肝硬化患者血清MicroRNA(miR)-122的表达水平与肝硬化Child-Pugh分级及并发症的关系。方法肝硬化患者87例,采用PCR实时荧光定量法测定患者血清miR-122水平,根据Child-Pugh分级对肝硬化患者进行分级,分析血清miR-122与肝硬化分级的关系。结果并发肝硬化腹水、消化道出血、自发性细菌性腹膜炎及失代偿期患者血清miR-122表达水平均高于未发生患者(P<0.05);不同肝硬化Child-Pugh分级血清中miR-122水平有统计学差异(P<0.05),A级与B级肝硬化患者血清miR-122水平无显著差异(P>0.05),A级和B级患者水平均显著低于C级(P<0.05)。多变量线性相关性显示,血清miR-122与丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、γ-谷氨酰转移酶(GGT)、碱性磷酸酶(ALP)呈正相关(P<0.05);与国际标准化比值(INR)及肌酐(Cr)水平呈负相关(P<0.05)。结论血清miR-122水平上升提示肝硬化已经失代偿,并与腹水、消化道出血、肝肾衰竭有关。因此,血清miR-122可作为评价肝硬化患者肝脏功能及预后的潜在生物学指标。     

MiR-876-5p acts as an inhibitor in hepatocellular carcinoma progression by targeting DNMT3A

Hepatocellular carcinoma (HCC) is one of the biggest challenges that human beings faced with in 21st century. Previous researches have revealed that miRNAs can serve as regulators in various cancers. MiR-876-5p, a member of miRNA family, has been studied in lung cancer for its anti-oncogenic function. However, the exact function of it is not reported in HCC. Our study aims to find out the effects of miR-876-5p expression on HCC progression. Two HCC cells were chosen to do functional assays after miR-876-5p expression was detected in cell lines by qRT-PCR. HepG2 cell was transfected with miR-876-5p mimics, whereas LM3 cell was transfected with miR-876-5p inhibitors. Next, cell activities of these two indicated cells were analyzed by means of MTT assay, colony forming assay, transwell migration assay and western blot analysis. Consequently, we found that miR-876-5p could inhibit both cell proliferation and metastasis. Moreover, we found out a target gene (DNMT3A) of miR-876-5p by performing bioinformatics analysis, dual luciferase reporter assay and biotin-avidin pull-down assay. Finally, rescue assays were carried out in HepG2 cells. We found that DNMT3A could reverse miR-876-5p mimics-induced inhibition. Therefore, we concluded that miR-876-5p suppressed hepatocellular carcinoma progression by targeting DNMT3A.     

mTOR负调控miR-27a并通过靶向降低GP73抑制人肝癌细胞侵袭

目的探索m TOR促进肝癌细胞侵袭能力机理。方法使用q-PCR方法检测miR-27a和GP73表达;将miR-27a的mimic转染GP73高表达的M97H细胞中,并将miR-27a inhibitor转入GP73低表达Hep G2细胞中,q-PCR和Western blot观察GP73的表达;使用荧光素酶报告基因系统验证miR-27a在GP73的3UTR区的结合位点;将miR-27a mimic转染GP73高表达的M97H细胞和GP73低表达的Hep G2细胞,Transwell实验观察细胞的侵袭。结果m TOR下调miR-27a,并上调GP73的表达;miR-27a下调GP73的表达,抑制miR-27a则上调GP73;GP73是miR-27a的靶基因;miR-27a显著抑制M97H细胞的侵袭,但对Hep G2细胞无抑制效果。结论 m TOR负调控的miR-27a靶向GP73抑制肝癌细胞的侵袭。     

miR-126抑制结肠癌增殖及侵袭转移的功能研究

目的：研究 miR-126在体内是否具有抑制结肠癌细胞增殖及侵袭转移的功能。方法利用慢病毒载体构建稳定过表达miR-126的结肠癌细胞系 HCT116,将实验组及对照组细胞分别进行裸鼠皮下及尾静脉成瘤体内实验。结果成功构建稳定过表达 miR-126细胞系 HCT116;裸鼠皮下成瘤实验结果显示过表达 miR-126实验组皮下移植瘤瘤体平均体积明显小于其对照组瘤体体积（P ＜0．05）;尾静脉成瘤组中稳定过表达 miR-126实验组肺部转移灶的平均数目、面积均明显小于其对照组（P＜0．05）。结论裸鼠移植瘤实验证实 miR-126在体内具有抑制结肠癌细胞增殖及侵袭转移的作用。     

低氧对SH-SY5Y细胞miR-124及BACE1蛋白表达的影响

目的研究低氧对培养细胞miR-124及β-淀粉样前体蛋白裂解酶1(BACE1)蛋白表达的影响。方法培养人神经母细胞瘤细胞(SH-SY5Y),分为对照组、氧-糖剥夺组、Aβ1-42处理组、过表达或抑制miR-124组,用实时定量PCR方法检测miR-124表达,Western blot法检测BACE1蛋白表达。结果氧-糖剥夺处理48 h,细胞内miR-124表达水平明显下降,仅为对照组的46.9%(P0.05),BAE1蛋白表达水平与较对照组增高36%(P0.01);转染miR-124过表达组组细胞内miR-124表达水平较对照组增高245倍(P0.01),为miR-124过表达对照组的219倍(P0.01),BACE1蛋白表达水平较对照组下降了29%(P0.05),较miR-124过表达对照组下降25%(P0.05)。转染miR-124抑制剂组miR-124表达水平下降至对照组的45.4%(P0.05),至miR-124抑制对照组的48%(P0.05),BACE1表达水平较对照组升高21%(P0.05),较miR-124抑制对照组升高40.3%(P0.01);细胞经Aβ1-42处理24 h,miR-124表达水平较对照组下降52%(P0.05),BACE1蛋白表达水平较对照组增高51%(P0.05)。结论低氧通过降低SH-SY5Y细胞miR-124表达进而升高BAEC1蛋白表达,且可能在阿尔茨海默病(Alzheimer's disease,AD)早期发病中发挥作用。     

miR-124在肿瘤研究中的进展

MicroRNA(miRNA)是一类在生物体内广泛表达的非编码小分子RNA,不仅参与调节生物体的生长发育,还与包括肿瘤在内的多种疾病的发生发展密切相关。miR-124就是其中之一,它是一个高度保守的抑癌miRNA。研究发现miR-124在多种肿瘤中均表达下调,已被证实在该类肿瘤的发生、发展以及预后中起着重要作用。     

大鼠肝脏发育成熟及癌变时miR-100的表达

目的：探讨microRNA-100(miR-100)在大鼠肝脏发育成熟和癌变时的表达。方法取新生SD乳鼠、成年SD大鼠肝组织以及经连续喂饲2-乙酰氨基芴加部分肝切除术(2-AAF/PH)诱导的SD大鼠肝癌组织,分别采用实时荧光定量PCR及FISH技术检测miR-100的表达。结果同新生SD乳鼠相比,miR-100在成年SD大鼠肝组织中表达明显升高( P<0．05)。大鼠肝脏癌变组织的miR-100表达较成年大鼠肝组织明显下降( P<0．05),接近于新生SD乳鼠miR-100的表达水平。结论 miR-100可作为SD大鼠肝脏发育成熟的标志,其表达降低可能与肿瘤形成有关。     

Distinct microRNA expression profiles in acute myeloid leukemia with common translocations

MicroRNAs (miRNAs) are postulated to be important regulators in cancers. Here, we report a genome-wide miRNA expression analysis in 52 acute myeloid leukemia (AML) samples with common translocations, including t(8;21)/AML1(RUNX1)-ETO(RUNX1T1), inv(16)/CBFB-MYH11, t(15;17)/PML-RARA, and MLL rearrangements. Distinct miRNA expression patterns were observed for t(15;17), MLL rearrangements, and core-binding factor (CBF) AMLs including both t(8;21) and inv(16) samples. Expression signatures of a minimum of two (i.e., miR-126/126*), three (i.e., miR-224, miR-368, and miR-382), and seven (miR-17-5p and miR-20a, plus the aforementioned five) miRNAs could accurately discriminate CBF, t(15;17), and MLL-rearrangement AMLs, respectively, from each other. We further showed that the elevated expression of miR-126/126* in CBF AMLs was associated with promoter demethylation but not with amplification or mutation of the genomic locus. Our gain- and loss-of-function experiments showed that miR-126/126* inhibited apoptosis and increased the viability of AML cells and enhanced the colony-forming ability of mouse normal bone marrow progenitor cells alone and particularly, in cooperation with AML1-ETO, likely through targeting Polo-like kinase 2 (PLK2), a tumor suppressor. Our results demonstrate that specific alterations in miRNA expression distinguish AMLs with common translocations and imply that the deregulation of specific miRNAs may play a role in the development of leukemia with these associated genetic rearrangements.